PL2205273T3 - Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego - Google Patents

Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego

Info

Publication number
PL2205273T3
PL2205273T3 PL08845159T PL08845159T PL2205273T3 PL 2205273 T3 PL2205273 T3 PL 2205273T3 PL 08845159 T PL08845159 T PL 08845159T PL 08845159 T PL08845159 T PL 08845159T PL 2205273 T3 PL2205273 T3 PL 2205273T3
Authority
PL
Poland
Prior art keywords
treatment
multiple sclerosis
modified cells
cells
modified
Prior art date
Application number
PL08845159T
Other languages
English (en)
Inventor
Roland Martin
Andreas Lutterotti
Stephen Miller
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of PL2205273T3 publication Critical patent/PL2205273T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08845159T 2007-10-31 2008-10-31 Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego PL2205273T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075952A EP2057998A1 (en) 2007-10-31 2007-10-31 Use of modified cells for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
PL2205273T3 true PL2205273T3 (pl) 2017-09-29

Family

ID=39167402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08845159T PL2205273T3 (pl) 2007-10-31 2008-10-31 Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego

Country Status (8)

Country Link
US (1) US8673293B2 (pl)
EP (2) EP2057998A1 (pl)
DK (1) DK2205273T3 (pl)
ES (1) ES2601329T3 (pl)
HU (1) HUE030745T2 (pl)
PL (1) PL2205273T3 (pl)
PT (1) PT2205273T (pl)
WO (1) WO2009056332A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
CA2750098A1 (en) * 2009-01-20 2010-07-29 Myelin Repair Foundation, Inc. Compositions and methods for induction of antigen-specific tolerance
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2637697A4 (en) 2010-11-12 2016-07-13 Cour Pharmaceuticals Dev Company MODIFIED IMMUNOMODULATING PARTICLES
EP3467509B1 (en) * 2011-05-04 2025-11-26 Cellular Technology, Ltd Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
RU2656156C2 (ru) 2011-10-17 2018-05-31 Массачусетс Инститьют Оф Текнолоджи Внутриклеточная доставка
KR102283760B1 (ko) 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
CA3261641A1 (en) 2013-03-13 2025-06-12 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
RS59801B2 (sr) 2013-08-13 2024-03-29 Univ Northwestern Čestice konjugovane peptidom
KR102304167B1 (ko) 2013-08-16 2021-09-24 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
RU2739794C2 (ru) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
US10526573B2 (en) 2014-11-14 2020-01-07 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
US11125739B2 (en) 2015-01-12 2021-09-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP7602702B2 (ja) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド 寛容性を誘導するための生体分子の細胞内送達
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
JP7359695B2 (ja) 2017-03-29 2023-10-11 ネオギャップ・セラピューテックス・アーベー 多発性硬化症に関連する自己抗原並びに治療及び診断でのその使用
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
AU2019265734B2 (en) 2018-05-09 2026-03-19 Anokion Sa Compositions and methods concerning immune tolerance
EP3586866A1 (en) 2018-06-28 2020-01-01 Universität Zürich Immunodominant proteins and fragments in multiple sclerosis
IL307722A (en) 2021-04-16 2023-12-01 Cour Pharmaceuticals Dev Company Inc A method of monitoring the existence of immunological tolerance
EP4119948A1 (en) 2021-07-16 2023-01-18 Universität Zürich Method for stratification and treatment of multiple sclerosis
JP2024529354A (ja) 2021-07-16 2024-08-06 ウニヴェルジテート・チューリッヒ 多発性硬化症を層別化および処置するための方法
EP4611796A1 (en) 2022-11-01 2025-09-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis
TW202535910A (zh) 2023-11-10 2025-09-16 蘇黎世大學 肽及其用於治療及/或預防多發性硬化症之用途
EP4553083A1 (en) 2023-11-10 2025-05-14 Cellerys AG Peptides and their use for the treatment and/or prevention of multiple sclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
HUE030745T2 (en) 2017-05-29
US8673293B2 (en) 2014-03-18
US20110033426A1 (en) 2011-02-10
WO2009056332A1 (en) 2009-05-07
ES2601329T3 (es) 2017-02-14
DK2205273T3 (en) 2016-12-19
EP2205273A1 (en) 2010-07-14
PT2205273T (pt) 2016-12-29
EP2057998A1 (en) 2009-05-13
EP2205273B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
SI2954932T1 (sl) Terapevtska uporaba diaminofenotiazinov
GB0908173D0 (en) Process for facilitating the management of care
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
GB0722680D0 (en) Therapeutic compounds and their use
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB0909297D0 (en) Composition for the treatment of skin conditions
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0710981D0 (en) New Therapeutic use
GB0708452D0 (en) Treatment of nuclear studge
IL206189A (en) Compounds for use in cancer treatment
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
GB0723100D0 (en) Treatment of HFnEF
GB2451349B (en) Epicondylitis treatment
GB0808690D0 (en) Therapeutic use
IL184620A0 (en) Composition for the treatment of inflammation
GB0705517D0 (en) Therapeutic compounds and their use
GB0602857D0 (en) The treatment of sialorrhoea
GB0609792D0 (en) The treatment of multiple sclerosis
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0809319D0 (en) The treatment of puritus